ZYME•benzinga•
Zymeworks Reports Last Patient Enrolled In Pivotal Study Of Zanidatamab In Treatment Of HER2-Expressing Late-Line Biliary Tract Cancer
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on April 28, 2022 by benzinga